• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Consumer Cyclical·MAPB.JK
Share

PT Map Boga Adiperkasa Tbk Stocks

IDR 1125Last Updated 23.10.2026

Issuer Rating

2/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

IDR 159.75M

IDR 1125
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Map Boga Adiperkasa Tbk, through its subsidiaries, operates cafes and restaurants in Indonesia. The company operates through Beverages; Foods; and Others segments. It operates a portfolio of Starbucks, Pizza Marzano, Krispy Kreme, Cold Stone Creamery, Genki Sushi, GODIVA Chocolatier, PAUL Bakery, and Subway brands. The company was formerly known as PT Creasi Aksesoris Indonesia and changed its name to PT Map Boga Adiperkasa Tbk in March 2016. PT Map Boga Adiperkasa Tbk was incorporated in 2013 and is headquartered in Jakarta Pusat, Indonesia. PT Map Boga Adiperkasa Tbk operates as a subsidiary of PT Mitra Adiperkasa Tbk.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA, trading

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

24.10.2026 04:37

A key Novartis drug failed to meet expectations. The stock price fell

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026